Sign In

Login

Password

Forgot Password ? Sign Up

Eptinezumab (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Eptinezumab" in Indonesian language version.

refsWebsite
Global rank Indonesian rank
7web.archive.org
1st place
1st place
2tga.gov.au
3,984th place
4,575th place
2nih.gov
4th place
13th place
2europa.eu
68th place
182nd place
2fda.gov
447th place
792nd place
1alderbio.com
low place
low place
1hres.ca
low place
low place
1canada.ca
1,712th place
7,978th place
1doi.org
2nd place
4th place
1semanticscholar.org
11th place
330th place
1handle.net
102nd place
411th place

alderbio.com (Global: low place; Indonesian: low place)

investor.alderbio.com

  • "Alder BioPharmaceuticals Initiates PROMISE 2 Pivotal Trial of Eptinezumab for the Prevention of Migraine" (Press release). Alder Biopharmaceuticals. 28 November 2016. Diarsipkan dari asli tanggal 9 August 2017. Diakses tanggal 28 December 2016.

canada.ca (Global: 1,712th place; Indonesian: 7,978th place)

doi.org (Global: 2nd place; Indonesian: 4th place)

  • Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, et al. (November 2014). "Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial". The Lancet. Neurology. 13 (11): 1100–1107. doi:10.1016/S1474-4422(14)70209-1. PMID 25297013. S2CID 206161999.

europa.eu (Global: 68th place; Indonesian: 182nd place)

ema.europa.eu

  • "Vyepti EPAR". European Medicines Agency (EMA). 11 November 2021. Diarsipkan dari versi aslinya tanggal 8 June 2022. Diakses tanggal 8 June 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

fda.gov (Global: 447th place; Indonesian: 792nd place)

accessdata.fda.gov

fda.gov

handle.net (Global: 102nd place; Indonesian: 411th place)

hdl.handle.net

hres.ca (Global: low place; Indonesian: low place)

hpr-rps.hres.ca

nih.gov (Global: 4th place; Indonesian: 13th place)

dailymed.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov

  • Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, et al. (November 2014). "Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial". The Lancet. Neurology. 13 (11): 1100–1107. doi:10.1016/S1474-4422(14)70209-1. PMID 25297013. S2CID 206161999.

semanticscholar.org (Global: 11th place; Indonesian: 330th place)

api.semanticscholar.org

  • Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, et al. (November 2014). "Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial". The Lancet. Neurology. 13 (11): 1100–1107. doi:10.1016/S1474-4422(14)70209-1. PMID 25297013. S2CID 206161999.

tga.gov.au (Global: 3,984th place; Indonesian: 4,575th place)

  • "Vyepti". Therapeutic Goods Administration (TGA). 24 June 2021. Diarsipkan dari versi aslinya tanggal 6 September 2021. Diakses tanggal 6 September 2021.
  • "AusPAR: Eptinezumab". Therapeutic Goods Administration (TGA). 3 March 2022. Diarsipkan dari versi aslinya tanggal 24 March 2022. Diakses tanggal 23 March 2022.

web.archive.org (Global: 1st place; Indonesian: 1st place)

  • "Alder BioPharmaceuticals Initiates PROMISE 2 Pivotal Trial of Eptinezumab for the Prevention of Migraine" (Press release). Alder Biopharmaceuticals. 28 November 2016. Diarsipkan dari asli tanggal 9 August 2017. Diakses tanggal 28 December 2016.
  • "Vyepti". Therapeutic Goods Administration (TGA). 24 June 2021. Diarsipkan dari versi aslinya tanggal 6 September 2021. Diakses tanggal 6 September 2021.
  • "AusPAR: Eptinezumab". Therapeutic Goods Administration (TGA). 3 March 2022. Diarsipkan dari versi aslinya tanggal 24 March 2022. Diakses tanggal 23 March 2022.
  • "Summary Basis of Decision (SBD) for Vyepti". Health Canada. 23 October 2014. Diarsipkan dari versi aslinya tanggal 30 May 2022. Diakses tanggal 29 May 2022.
  • "Vyepti- eptinezumab-jjmr injection". DailyMed. Diarsipkan dari versi aslinya tanggal 28 September 2021. Diakses tanggal 27 September 2021.
  • "Vyepti EPAR". European Medicines Agency (EMA). 11 November 2021. Diarsipkan dari versi aslinya tanggal 8 June 2022. Diakses tanggal 8 June 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  • "Drug Trials Snapshots: Vyepti". U.S. Food and Drug Administration (FDA). 21 February 2020. Diarsipkan dari versi aslinya tanggal 30 September 2020. Diakses tanggal 17 March 2020. Artikel ini memuat teks dari sumber tersebut, yang berada dalam ranah publik.